North American Breast Cancer Therapeutics Market size is predicted to reach USD 16 billion by 2028, according to a latest forecast report by Graphical Research.
Technological developments in cancer biology, breast cancer therapeutics, and diagnostics is anticipated to proliferate the market growth. Over the past years, significant developments have been made in the field of drug discovery & therapeutics for breast cancer. Revised understanding regarding biologic heterogeneity of breast cancer has enabled the development of increasingly effective and personalized therapeutic approach. The ongoing research activities to improve the current breast cancer screening methods have led to the development of 3-D mammography, also called breast tomosynthesis. This approach incorporates images from different angles and generates a 3-D image. Similarly, the increasing use of artificial intelligence in breast cancer detection have facilitated early detection, thereby enabling the patients to undergo optimal therapeutics with increased survival rate. Radiologists employ artificial intelligence (AI) based algorithms to aid in better assessment of mammograms. Certain clinical studies reveal that the use of AI leads to more precise results in diagnosis of breast cancer. Also, the use of nanotechnology in cancer detection and treatment offers multiple advantages over the conventional approach. This approach incorporates nanoparticles in chemotherapy, and this combination enables targeting the cancer cells directly with fewer harmful side effects.
Increasing research & development activities, clinical trial studies, and investments by major companies as well as research institutes are set to fuel the North America breast cancer therapeutics market demand. For instance, National Cancer Institute (NCI) funds a host of activities concerning breast cancer screening and therapeutics. NCI-sponsored clinical trial studies such as TAILORx and RxPONDER trial that have led to advents in certain gene expressions that aids in determining treatment options in women with advanced breast cancer. Similarly, NCI provides financial resources for large-scale breast screening trial referred to as the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), to assess advanced cancers detection using 3-D mammography.
Browse detailed statistical insights from the report, “North America Breast Cancer Therapeutics Market Forecast 2028 By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
The chemotherapy segment held around 9% North America breast cancer therapeutics market share in 2021 and will surpass USD 1.3 billion by 2028, owing to growing preference for chemotherapy and ability to be used in combination with other breast cancer therapeutics. For instance, chemotherapy is the standard therapeutic solution preferred alone or in combination with other agents in HER2+ breast cancer and triple negative breast cancer. Keytruda is also approved as a therapeutic agent in combination with chemotherapy as a first-line treatment in patients that feature protein PD-L1 presence. Similarly, in April 2020, the U.S. FDA approved Trodelvy (sacituzumab govitecan-hziy) to treat metastatic triple-negative breast in combination with chemotherapy. This drug conjugate assists in minimizing the damage to the healthy tissue. As a result, versatility and novel product launches concerning chemotherapy is set to boost the chemotherapy segment.
Canada breast cancer therapeutics market accounted over USD 595 million revenue in 2021 and will expand at 7.9% CAGR through 2028, attributed to the increasing prevalence of breast cancer, facilitative government initiatives, and growing health expenditure in the country. As per the Canadian Cancer Society statistics, in 2021, an estimated 1 among 8 Canadian women are expected to be diagnosed with breast cancer. The statistics further highlight that in 2021, around 27,700 Canadian women were diagnosed with breast cancer, representing 25% of all new cancer cases in women. Also, the projections indicate that from 2015 to 2030, the incidence of diagnosed cancer cases is anticipated to surge by approximately 40%. The high prevalence of breast cancer is expected to drive the demand for breast cancer therapeutics. Additionally, the local government in Canada announced a High-Risk Breast Cancer Project that intends to promote the awareness and knowledge among women.
The North American breast cancer therapeutics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2017 to 2028, for the following segments:
North America Market, By Therapy
- Targeted Therapy
- Hormonal Therapy
The above information has been provided for the following countries: